Differential expression of gene in pan-cancer: A potential biomarker for survival and immunotherapy.

T-cell immunoglobulin mucin 3 (TIM-3) has emerged as a promising immune checkpoint target in cancer therapy. However, the profile of the hepatitis A virus cellular receptor 2 () gene, encoding TIM-3 expression, is still obscure, along with its role in cancer immunity and prognosis. This study comprehensively analyzed expression patterns in pan-cancer and underlined its potential value for immune checkpoint inhibitor-based immunotherapy. Our results displayed that was differentially expressed and closely corresponded to survival status in pan-cancer. More importantly, the expression level was also significantly related to cancer immune infiltration, immune checkpoint genes, and immune marker genes. Enrichment analyses implicated -associated terms in cancer, including immunity, metabolism, and inflammation. Our study demonstrated that could participate in differing degrees of immune infiltration in tumorigenesis. The highlights of the pathway revealed that TIM-3 could function as both a biomarker and clinical target to improve the therapeutic efficacy of immunotherapy.